

**Subject:** Medical Science Liaison (MSL) Notes - Introduction of PulmoVive

**Date:** August 10, 2024

**Provider:** Dr. Jonathan Reynolds

**Title:** Pulmonologist

**Institution:** RespiraLung Pulmonary Clinic

**Summary of Key Discussion Points:**

**1. Introduction:**

- Introduced PulmoVive as an innovative therapy for managing moderate to severe chronic obstructive pulmonary disease (COPD).
- Emphasized its unique mechanism targeting both bronchoconstriction and airway inflammation.

**2. Provider's Current Patient Cases:**

- Dr. Reynolds expressed interest in new interventions for patients experiencing exacerbations despite standard COPD treatments.
- Discussed specific cases where current bronchodilators and anti-inflammatory agents have shown limited efficacy.

**3. Efficacy and Clinical Data:**

- Presented recent clinical data showcasing PulmoVive's ability to improve FEV1 by 15% and reduce exacerbation rates by 30%.
- Highlighted statistically significant improvements in quality of life scores and exercise tolerance.

**4. Safety Profile:**

- Discussed the favorable safety profile of PulmoVive, with a low incidence of respiratory adverse events.
- Dr. Reynolds inquired about potential interactions with commonly prescribed medications in COPD management.

**5. Mechanism of Action:**

- Explained PulmoVive's dual mechanism, focusing on bronchodilation and modulation of inflammatory pathways.
- Dr. Reynolds appreciated the drug's unique approach and sought insights into its impact on preventing disease progression.

**6. Patient Adherence and Education:**

- Discussed strategies for enhancing patient adherence through a once-daily inhaler and convenient administration.

- Shared patient education materials emphasizing the importance of early intervention in COPD management.

**7. Emerging Research and Future Developments:**

- Highlighted ongoing research on PulmoVive's potential in addressing comorbidities associated with COPD, such as cardiovascular risk.
- Discussed plans for exploring combination therapies to optimize overall respiratory health.

**8. Competitive Landscape:**

- Compared PulmoVive to existing COPD therapies, emphasizing its dual-action mechanism and potential for comprehensive disease management.
- Discussed the need for tailoring treatments to individual patient profiles in COPD care.

**9. Access and Reimbursement:**

- Provided updates on access and reimbursement programs for pulmonary clinics.
- Discussed potential affordability concerns and patient assistance programs.

**10. Action Items and Follow-Up:**

- Dr. Reynolds expressed interest in participating in ongoing real-world evidence studies for PulmoVive.
- Agreed upon a follow-up in three months to provide additional data and address any ongoing concerns.

**11. Closing Remarks:**

- Expressed gratitude for Dr. Reynolds's commitment to advancing respiratory care.
- Reiterated commitment to ongoing collaboration and support for the RespiraLung Pulmonary Clinic.